Endpoints News 生物医药· Elizabeth Cairns·· 2026-10-19AI 评分54
AbbVie称Skyrizi组合疗法在中期克罗恩病试验中优于单药
AbbVie’s Skyrizi combo beats Skyrizi alone in mid-stage Crohn’s trial
AI 导读
AbbVie于周一表示,以Skyrizi为基础、用于炎症性肠病的组合疗法在克罗恩病中期试验中效果优于Skyrizi单药。可读部分未披露具体疗效数据、组合中的另一药物及试验规模。
正文
AbbVie’s Skyrizi-based combination therapy for inflammatory bowel disease worked better than Skyrizi alone in a mid-stage trial in Crohn’s disease, the company said Monday.
The …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
来源:Endpoints News 生物医药 · endpoints.news